MultiCell Technologies Inc (MCET)

[TPX]

Hepatitis B Pipeline Review, Therapeutics Development and Vaccine H1 2017

June 1, 2017

The research report “Hepatitis B – Pipeline Review, H1 2017” provides comprehensive information on the therapeutics under development for Hepatitis B , with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Hepatitis B pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Companies Involved in Therapeutics Development are ... MultiCell Technologies Inc, ...

Complete research report on H1 2017 pipeline review of Hepatitis B with 20 market data tables and 7 figures, spread across 353 pages is available at https://www.marketinsightsreports.com/report/purchase/060128937?mode=su

The Hepatitis B pipeline guide also reviews of key players involved in therapeutic development for Hepatitis B and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 8, 27, 26, 4, 56, 35 and 4 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 3, 9 and 5 molecules, respectively.

Scope of this report: The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis B. The pipeline guide reviews pipeline therapeutics for Hepatitis B by companies and universities/research institutes based on information derived from company and industry-specific sources. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. The pipeline guide reviews key companies involved in Hepatitis B (Infectious Disease) therapeutics and enlists all their major and minor projects. The pipeline guide evaluates Hepatitis B (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis B.

http://www.tradecalls.org/2017-06-01-hepatitis-b-pipeline